Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Martin Schuler,Kristof Cuppens,Till Plönes,Marcel Wiesweg,Bert Du Pont,Balazs Hegedus,Johannes Köster,Fabian Mairinger,Kaid Darwiche,Annette Paschen,Brigitte Maes,Michel Vanbockrijck,David Lähnemann,Fang Zhao,Hubertus Hautzel,Dirk Theegarten,Koen Hartemink,Henning Reis,Paul Baas,Alexander Schramm,Clemens Aigner

DOI: https://doi.org/10.1038/s41591-024-02965-0

IF: 82.9

2024-05-02

Nature Medicine

Abstract:Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4, administered alone or in combination with chemotherapy, are the standard of care in most patients with metastatic non-small-cell lung cancers. When given before curative surgery, tumor responses and improved event-free survival are achieved. New antibody combinations may be more efficacious and tolerable. In an ongoing, open-label phase 2 study, 60 biomarker-unselected, treatment-naive patients with resectable non-small-cell lung cancer were randomized to receive two preoperative doses of nivolumab (anti-PD-1) with or without relatlimab (anti-LAG-3) antibody therapy. The primary study endpoint was the feasibility of surgery within 43 days, which was met by all patients. Curative resection was achieved in 95% of patients. Secondary endpoints included pathological and radiographic response rates, pathologically complete resection rates, disease-free and overall survival rates, and safety. Major pathological (≤10% viable tumor cells) and objective radiographic responses were achieved in 27% and 10% (nivolumab) and in 30% and 27% (nivolumab and relatlimab) of patients, respectively. In 100% (nivolumab) and 90% (nivolumab and relatlimab) of patients, tumors and lymph nodes were pathologically completely resected. With 12 months median duration of follow-up, disease-free survival and overall survival rates at 12 months were 89% and 93% (nivolumab), and 93% and 100% (nivolumab and relatlimab). Both treatments were safe with grade ≥3 treatment-emergent adverse events reported in 10% and 13% of patients per study arm. Exploratory analyses provided insights into biological processes triggered by preoperative immunotherapy. This study establishes the feasibility and safety of dual targeting of PD-1 and LAG-3 before lung cancer surgery.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper published in "Nature Medicine" explored the **safety and feasibility of nivolumab (a PD - 1 inhibitor), with or without relatlimab (a LAG - 3 inhibitor), in patients with resectable non - small - cell lung cancer (NSCLC) before surgery**. Specifically, the main objectives of the study were:

1. **To evaluate whether the combination of these two immune checkpoint inhibitors before surgery is safe and feasible**: The primary endpoint was to confirm whether all patients could undergo surgery successfully within 43 days.
2. **To evaluate the pathological and imaging response rates**: Including major pathological response (MPR, ≤10% viable tumor cells) and objective imaging response rate.
3. **To evaluate disease - free survival (DFS) and overall survival (OS)**: Especially for those patients who achieved major pathological response.
4. **To explore the changes in biomarkers and the immune microenvironment**: To understand which biological processes may be related to the treatment response.

### Background and Motivation

Non - small - cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. Despite advances in early detection techniques, most patients are still diagnosed at an advanced stage. In recent years, precision therapies targeting specific oncogenic mutations and monoclonal antibodies targeting PD - 1/PD - L1 and CTLA - 4 immune checkpoints have significantly improved the treatment outcomes of patients with metastatic NSCLC. However, the application of these therapies in locally resectable NSCLC still needs further exploration.

### Research Design

This was an open - label, randomized, phase II clinical trial (NCT04205552), and a total of 60 untreated patients with resectable NSCLC were recruited. Patients were randomly assigned to two treatment groups:
- **Group A**: Received only two doses of nivolumab (240 mg)
- **Group B**: Received two doses of nivolumab (240 mg) plus relatlimab (80 mg)

The primary endpoint of the study was to evaluate whether patients could complete the surgery successfully within 43 days. Secondary endpoints included pathological response rate, imaging response rate, disease - free survival, overall survival, and safety.

### Key Findings

1. **Surgical Feasibility**: All 60 patients had successful surgeries within 43 days, and 95% of the patients achieved radical resection (R0).
2. **Pathological Response**:
- The major pathological response rate in Group A (nivolumab) was 27%, and the complete pathological response rate was 13%.
- The major pathological response rate in Group B (nivolumab + relatlimab) was 30%, and the complete pathological response rate was 17%.
3. **Imaging Response**:
- The partial imaging response rate in Group A was 10%.
- The partial imaging response rate in Group B was 27%.
4. **Survival Rate**: After 12 - month follow - up, the disease - free survival rate in Group A was 89% and the overall survival rate was 93%; in Group B, the disease - free survival rate was 93% and the overall survival rate was 100%.
5. **Safety**: 40% of the patients in Group A had grade ≥3 adverse events, and 53% in Group B. The most common immune - related adverse event was thyroid dysfunction.

### Conclusions

This study shows that in patients with resectable NSCLC, the combined treatment of nivolumab and relatlimab before surgery is safe and feasible, can improve the pathological response rate, and shows a good survival prospect. In addition, this combined treatment regimen does not significantly increase toxicity, providing strong evidence for further optimizing the peri - operative treatment of NSCLC.

### Formula Representation

To ensure the correctness and readability of the formulas, the following are the Markdown formula representations of some key indicators involved in the paper:

- Major Pathological Response Rate (MPR):
\[
MPR=\frac{\text{Number of patients with major pathological response}}{\text{Total number of patients}}\times100\%
\]
- Complete Pathological Response Rate (pCR):
\[
pCR = \frac{\text{Number of patients with complete pathological response}}{\text{Total number of patients}}\times100\%
\]
- Partial Imaging Response Rate: